Two major announcements yesterday about COVID-19 vaccines could help address vaccine hesitancy.
The FDA approved Moderna’s COVID-19 vaccine,saying it “meets the FDA’s rigorous standards for safety, effectiveness, and manufacturing quality required for approval.” Spikevax has been available under emergency use authorization (EUA) since December 18, 2020.
What they’re saying: “Our COVID-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from COVID-19 infection, hospitalization, and death,” said Moderna CEO Stéphane Bancel. “The full licensure of Spikevax in the U.S. now joins that in Canada, Japan, the European Union, the UK, Israel, and other countries, where the adolescent indication is also approved.”
Why it matters: “While hundreds of millions of doses of Moderna COVID-19 Vaccine have been administered to individuals under emergency use authorization, we understand that for some individuals, FDA approval of this vaccine may instill additional confidence in making the decision to get vaccinated,” said Acting FDA Commissioner Dr. Janet Woodcock.
Throwback: Moderna’s CEO on the I am BIO Podcast on March 30, 2020
Also: Novavax applied for EUA for its COVID vaccine,the company announced.
The vaccine uses “Novavax’s recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein,”the company says. The vaccine has shown to be highly effective including against the Delta variant.
Watch: How do we protect ourselves against COVID-19 variants?
Why it matters: “We believe our vaccine offers a differentiated option built on a well-understood protein-based vaccine platform that can be an alternative to the portfolio of available vaccines to help fight the COVID-19 pandemic,” said Novavax President and CEO Stanley C. Erck.
Read: Inside Novavax, the Maryland biotech with a promising COVID-19 vaccine
More Health Care News:
The Wall Street Journal (Opinion): Robert Califf for the FDA
“Dr. Califf doesn’t deserve the abuse. In 2016 the Senate confirmed him as FDA Commissioner, 89-4, and he led the agency for 10 months without major controversy. The pandemic has shown how crucial it is to have competent FDA leadership, especially in this era of biotech innovation and therapeutic breakthroughs,” says The Wall Street Journal Editorial Board.
The Washington Post (Opinion): Antibiotic resistance is growing
“We need better stewardship of antibiotics—avoiding overprescribing or wrongly prescribing them for viral infections. More attention must be devoted to preventing resistant infections in the first place. Accelerated development of new antibiotics is essential,” says The Washington Post Editorial Board.